Provided by Tiger Fintech (Singapore) Pte. Ltd.

Glaukos

112.21
+3.062.80%
Post-market: 112.210.00000.00%16:17 EST
Volume:1.02M
Turnover:112.44M
Market Cap:6.34B
PE:-40.44
High:113.42
Open:107.18
Low:105.53
Close:109.15
Loading ...

Company Profile

Company Name:
Glaukos
Exchange:
NYSE
Establishment Date:
1998
Employees:
995
Office Location:
One Glaukos Way,Aliso Viejo,California,United States
Zip Code:
92656
Fax:
949 367 9984
Introduction:
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Directors

Name
Position
Thomas W. Burns
President, Chief Executive Officer and Director
William J. Link
Chairman of our Board
Aimee S. Weisner
Director
David F. Hoffmeister
Director
Gilbert H. Kliman
Director
Jonathan T. Silverstein
Director
Marc A. Stapley
Director
Mark J. Foley
Director

Shareholders

Name
Position
Thomas W. Burns
President, Chief Executive Officer and Director
Chris M. Calcaterra
Chief Commercial Officer and Chief Operating Officer
Richard L. Harrison
Treasurer and Chief Financial Officer